Physician profile
Lloyd Williams
NPI 1871565531
$6,430.85
in general payments reported to CMS, 2019-2025
50 companies · $1,415 in 2025
The $1,415 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $199 · 2021: $1,091 · 2022: $1,055 · 2023: $1,002 · 2024: $1,113 · 2025: $1,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,530.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,207.42 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $742.30 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $666.52 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $541.28 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.87 | 2019-2025 | Jardiance |
| Pfizer INC. | $210.40 | 2019-2025 | |
| Amarin Pharma, INC. | $203.84 | 2019-2022 | |
| Astellas Pharma US INC | $198.34 | 2020-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $181.26 | 2019-2024 | |
| Amgen INC. | $165.58 | 2021-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $150.04 | 2021-2024 | |
| Axsome Therapeutics, INC. | $126.04 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.14 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $116.22 | 2019-2023 | Xarelto |
| Sunovion Pharmaceuticals INC. | $103.76 | 2019-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lloyd Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.